Filing summary
Entity mismatch: The request identifies Riot Platforms, Inc., but the supplied Form 10-Q is for Venaxis, Inc. Do not attribute these results to Riot Platforms without verifying the filing. The report covers the unaudited quarter and six months ended June 30, 2014.
Business context and financial results
Venaxis was developing and commercializing APPY 1, an acute appendicitis diagnostic test, and developing a next-generation product, APPY 2. It completed its pivotal APPY 1 clinical trial in January 2014 and submitted a 510(k) application to the FDA in March. The company had CE marking for EU commercialization.
- Quarter: No product sales; $24,174 of license-fee revenue; operating loss of $2.60 million and net loss of $2.59 million, or $0.08 per share. The comparable 2013 quarter had no product sales, $21,249 of license revenue, and a $3.14 million net loss, or $0.21 per share.
- Six months: Product sales were $51,728, versus none in 2013; cost of sales was $31,907 and gross profit was $19,821. License-fee revenue was $47,349. Operating loss was $5.50 million and net loss was $5.54 million, or $0.21 per share, compared with a $5.95 million operating loss and $5.95 million net loss, or $0.48 per share, in 2013.
- Expenses: Six-month selling, general and administrative expense rose 28% to $3.57 million, primarily from commercialization, marketing, and compensation costs. Research and development expense fell 38% to $2.00 million as pivotal-trial work substantially wound down; about $535,000 went to APPY 2 development.
- Cash and liquidity: At June 30, cash and cash equivalents were $3.75 million and short-term investments were $25.35 million, totaling about $29.10 million in cash and liquid investments. Working capital was $27.80 million.
- Cash flow: Six-month operating cash use was $4.96 million, compared with $4.36 million in 2013. Investing cash use was $16.82 million, largely reflecting net purchases of short-term investments; financing provided $19.88 million. Cash declined by $1.91 million during the period.
- Debt and equity: Notes and other obligations totaled $2.22 million, primarily mortgage debt. In April, the company issued 8.335 million shares at $2.40 per share, generating about $20 million before approximately $1.54 million in fees and expenses. Shares outstanding were 30,990,029 at August 11, 2014.
Changes, outlook, and risks
Loss per share improved year over year, but remained substantial; the lower net loss reflected reduced R&D costs and the comparison was also affected by prior-year other income. Product revenue was limited to EU sales in the first half and there were no product sales in the second quarter.
Management expected continued near-term operating losses and said existing working capital, including April offering proceeds, was expected to fund estimated cash needs into 2015. It was exploring additional financing, partnerships, and licensing while pursuing APPY 1 commercialization and cost controls. Management cautioned that failure to obtain FDA clearance could require a strategic change or cessation of operations; insufficient product revenue could also affect recoverability of capitalized patent costs. There was no assurance that additional financing would be available on acceptable terms.
Other notable matters include an appeal in the Wolfe securities class action, which had been dismissed by the district court and remained under appellate consideration, and potential Ceva license milestones of up to $1.1 million, plus up to $2 million for additional products, and royalties if milestones and sales occur. The company reported no material changes to the risk factors in its 2013 Form 10-K. Management stated disclosure controls were effective and reported no material change in internal control over financial reporting.
Important facts to verify
- Confirm the issuer: the supplied filing is Venaxis, Inc., not Riot Platforms, Inc.
- Verify APPY 1’s FDA 510(k) review status and the timing and conditions for potential clearance.
- Assess the cash runway against ongoing operating cash use and management’s “into 2015” estimate, including access to further financing.
- Track product commercialization, customer concentration, and whether EU sales can grow beyond the limited first-half revenue reported.
- Review the appeal status of the Wolfe litigation and the potential dilution from outstanding options and warrants.